Comparative Cardiovascular Effectiveness and Safety of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors According to Frailty in Type 2 Diabetes.
Alexander KutzDae Hyun KimDeborah J WexlerJun LiuSebastian SchneeweissRobert J GlynnElisabetta PatornoPublished in: Diabetes care (2023)
SGLT-2is and GLP-1RAs safely improved cardiovascular outcomes and all-cause mortality, with the largest absolute benefits among frail people.